Ceftriaxone Dosage for Community-Acquired Pneumonia

(DC-CAP Trial)

Not yet recruiting at 1 trial location
JD
Overseen ByJonathan D Baghdadi, MD, PhD
Age: 18+
Sex: Any
Trial Phase: Phase 4
Sponsor: University of Maryland, Baltimore
Must be taking: Ceftriaxone
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

Aim: Demonstrate the equivalent efficacy and superior safety of Ceftriaxone 1 gram daily compared with Ceftriaxone 2 grams daily among hospitalized patients with community-acquired pneumonia who are not admitted to the intensive care unit.\<p\>

Hypothesis: Among hospitalized patients outside of the intensive care unit with community-acquired pneumonia who are prescribed Ceftriaxone, a dosage of 1 gram daily will be associated with an equivalent rate of clinical cure and fewer adverse events than a dosage of 2 grams daily.

Are You a Good Fit for This Trial?

Inclusion Criteria

* Evaluated in the emergency department or within 72 hours of hospitalization
I have been prescribed Ceftriaxone for pneumonia I got outside the hospital.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants receive either 1 gram or 2 grams of Ceftriaxone daily for community-acquired pneumonia

Up to 8 days

Follow-up

Participants are monitored for safety and effectiveness after treatment

120 days

What Are the Treatments Tested in This Trial?

Interventions

  • Ceftriaxone

How Is the Trial Designed?

2

Treatment groups

Active Control

Group I: Low Dose CeftriaxoneActive Control1 Intervention
Group II: Moderate Dose CeftriaxoneActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Maryland, Baltimore

Lead Sponsor

Trials
729
Recruited
540,000+